[chamada] National Institutes of Health (NIH) – Gene Fusions in Pediatric Sarcomas (R01 and R21)

14/09/2017 15:21

The overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics.

R01: October 05, 2017;
R21: October 16, 2017.

Letter of Intent Due Date(s):
30 days prior to the application due date.

Data de expiração:
May 8, 2020.

Mais informações em R01 R21.

Tags: BolsaEditalExteriorNIH